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Background: Small incision lenticule extraction or SMILE is a novel form of ‘flapless’ corneal refractive surgery that
was adapted from refractive lenticule extraction (ReLEx). SMILE uses only one femtosecond laser to complete the
refractive surgery, potentially reducing surgical time, side effects, and cost. If successful, SMILE could potentially
replace the current, widely practiced laser in-situ keratomileusis or LASIK. The aim of this study is to evaluate
whether SMILE is non-inferior to LASIK in terms of refractive outcomes at 3 months post-operatively.
Methods/Design: Single tertiary center, parallel group, single-masked, paired-eye design, non-inferiority,
randomized controlled trial. Participants who are eligible for LASIK will be enrolled for study after informed consent.
Each participant will be randomized to receive SMILE and LASIK in each eye. Our primary hypothesis (stated as null)
in this non-inferiority trial would be that SMILE differs from LASIK in adults (>21 years old) with myopia (> −3.00
diopter (D)) at a tertiary eye center in terms of refractive predictability at 3 months post-operatively. Our secondary
hypothesis (stated as null) in this non-inferiority trial would be that SMILE differs from LASIK in adults (>21 years
old) with myopia (> −3.00 D) at a tertiary eye center in terms of other refractive outcomes (efficacy, safety,
higher-order aberrations) at 3 months post-operatively. Our primary outcome is refractive predictability, which is
one of several standard refractive outcomes, defined as the proportion of eyes achieving a postoperative spherical
equivalent (SE) within ±0.50 D of the intended target. Randomization will be performed using random allocation
sequence generated by a computer with no blocks or restrictions, and implemented by concealing the
number-coded surgery within sealed envelopes until just before the procedure. In this single-masked trial, subjects
and their caregivers will be masked to the assigned treatment in each eye.
Discussion: This novel trial will provide information on whether SMILE has comparable, if not superior, refractive
outcomes compared to the established LASIK for myopia, thus providing evidence for translation into clinical practice.
Trial registration: Clinicaltrials.gov NCT01216475.
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Laser in-situ keratomileusis (LASIK) is the current laser
refractive procedure of choice to treat myopia. The advan-
tages of LASIK include early postoperative improvement
and stabilization of visual acuity, minimal postoperative
patient discomfort, and the possibility of enhancement in
the future [1]. However, side effects such as dry eyes,* Correspondence: jodmehta@gmail.com
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reproduction in any medium, provided the orreduced vision in low lighting conditions, and visual
distortions such as glare and haloes can still occur in up to
1% to 2% of cases; while flap-related complications,
inflammation, or infection, though rare, can have serious
consequences [2,3].
Femtosecond lasers have been widely used in LASIK to
fashion a corneal flap, which is followed by corneal ablation
using a separate excimer laser [4]. The advantages of femo-
tosecond or ‘bladeless’ LASIK over microkeratome LASIK
flaps are reduced postoperative dry-eye symptoms, reduced
likelihood of flap dislocation, and reduced incidence of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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extraction (ReLEx) has been introduced as a single laser
refractive procedure without the use of an excimer laser
[5-8]. Small incision lenticule extraction (SMILE) is a vari-
ation of ReLEx that requires no retractable flap, thus redu-
cing surgical time, reduced patient inconvenience from
moving from one laser to another, and, potentially, more
accurate ablation [8].
A review of current literature reveals that there are few
studies available to validate the outcome of ReLEx or
SMILE, which has obtained CE Mark approval in 2009 but
yet to be approved by the United States FDA [5-8]. Initial
clinical results have been promising, which found that post-
operative refractive outcomes after ReLEx were comparable
to LASIK with few complications [9,10]. However, there
are currently no randomized controlled trials comparing
both surgical procedures. We have also conducted prelim-
inary clinical and experimental studies with promising
results and confirmed the safety and efficacy of ReLEx [11].
Non-inferiority trials are used to compare standard
treatment with a new treatment that is expected to have
some advantages such as greater predictability, less side
effects, or greater improvement in quality of life [12,13].
LASIK, which is the current gold standard for corneal
refractive surgery, already produces good visual out-
comes with refractive predictability. As we do not expect
to see a great improvement to the results from the
already established LASIK, we aim to demonstrate that
SMILE is just as good in terms of visual outcome in this
randomized non-inferiority trial.
Methods/Design
Study objective and hypotheses
In this study we aim to demonstrate that the refractive
predictability of SMILE is not inferior to the established
procedure (LASIK) to treat myopia. Refractive predictabil-
ity is one of several standard refractive outcomes, defined
as the proportion (number) of eyes achieving a postopera-
tive spherical equivalent (SE) within ±0.50 diopter (D) of
the intended target. Our primary hypothesis (stated as
null) in this non-inferiority trial would be that SMILE
differs from LASIK in adults (>21 years old) with myopia
(> −3.00 D) at a tertiary eye center in terms of refractive
predictability at 3 months postoperatively. Our secondary
hypothesis (stated as null) in this non-inferiority trial would
be that SMILE differs from LASIK in adults (>21 years
old) with myopia (> −3.00 D) at a tertiary eye center in
terms of other refractive outcomes (efficacy, safety, higher-
order aberrations) at 3 months postoperatively.
Trial design
This trial is a single tertiary center, parallel group, single-
masked, paired-eye design, non-inferiority, randomized
controlled trial. We will use a paired-eye study design,with subjects randomly assigned to undergo one proced-
ure in each eye (SMILE in one eye, LASIK in the other
eye). All procedures will be performed in the SNEC
Refractive Center by the same fully qualified refractive sur-
geons, who are co-investigators in this study. Each surgeon
has performed more than 30 similar surgeries and 20 cases
of SMILE to ensure that each surgeon is adept at perform-
ing this procedure. After randomization and random allo-
cation to treatment group, each subject will undergo either
SMILE or LASIK in one eye, followed by LASIK or SMILE
in the fellow eye on the same day (either the left or right
eye will be randomized to decide which eye is operated on
first). We have obtained ethics approval from our Institu-
tional Review Board (CIRB Ref No: 2011/109/A) and this
trial has been registered (Clinical Trials Registration
NCT01216475).
Participants and recruitment
All participants with bilateral myopia will be recruited at
the Singapore National Eye Center (SNEC) with the inclu-
sion and exclusion criteria detailed in Table 1. All subjects
will be recruited and provide written informed consent
that explains the details of the trial, interventions, and




Each SMILE procedure will be performed using an
established, described technique [7]. After application of
topical anesthesia, standard sterile draping, and insertion
of the speculum, the patient’s eye will be centered and
docked with the curved interface cone before application
of suction fixation. The laser will then be activated for
photo-dissection in the following sequence: first the pos-
terior surface of the refractive lenticule (spiral in), then
the lenticule border is created. The anterior surface of
the refractive lenticule (spiral out) is then formed which
extended beyond the posterior lenticule diameter by
0.5 mm to form the anterior flap and is followed by a
rim cut. We will use the following FS laser parameters:
120 μm flap thickness, 7.5 mm flap diameter, 6.5 mm
optical zone of lenticule, 145 nj of power with side cut
angles at 90°. A superior hinge, 50° in cordal length, will
be made in all cases. The spot distance and tracking spa-
cing are 3/3 μm for the lenticule, 2.5/2.5 μm for the len-
ticule side cut, 3/3 μm for the flap, and 2/2 μm for the
flap side cut. After the suction is released, a Siebel spat-
ula (Rhein Medical, Heidelberg, Germany) is inserted
under the flap near the hinge before the flap is separated
and reflected. The edge of the refractive lenticule is
separated from the stromal bed with a sinsky hook and
the posterior border of the lenticule gently separated
with the Siebel spatula. The lenticule is then grasped
Table 1 Inclusion and exclusion criteria for trial participants
Inclusion criteria Exclusion criteria
I. 21 years of age or older I. Progressive or unstable myopia and/or astigmatism
II. Cycloplegic spherical equivalent of >−3.00 D in BOTH eyes II. Clinical or corneal topographic evidence of keratoconus
III. Refractive cylinder −2.00 D or less in BOTH eyes
and anisometropia of <1D comparing BOTH eyes
III. Residual, recurrent or active ocular disease such as uveitis,
severe dry eyes, severe allergic eye disease, glaucoma,
visually significant cataract, and retinal disease
IV. Best spectacle corrected visual acuity (BSCVA) of 6/12 or
better in BOTH eyes
IV. Previous corneal surgery or trauma within the corneal flap zone
V. Spherical or cylindrical error has progressed at −0.50 D
or less per year from date of baseline measurement
in BOTH eyes
V. Patent corneal vascularization within 1 mm of the corneal flap zone
VI. Contact lens wearers must have removed contact
lenses at least 2 weeks before the baseline measurement
VI. Taking systemic medications likely to affect wound healing,
such as corticosteroids and antimetabolites. Systemically
immunocompromised or systemic disease likely to affect
wound healing, such as diabetes, connective tissue disease,
and severe atopy; pregnant or nursing
VII. No evidence of irregular astigmatism on corneal topography in BOTH eyes
Ang et al. Trials 2012, 13:75 Page 3 of 5
http://www.trialsjournal.com/content/13/1/75with non-toothed serrated forceps through the small
incision.
LASIK procedure
Each LASIK procedure will be performed using a stand-
ard, established technique. Under topical anesthesia and
standard draping, a lid speculum is used to retract the eye-
lids, and polyvinyl acetate surgical spears (Ivalon, New
London, CT) to dry the conjunctival fornices. A superiorly
hinged 120/140 μm thick flap will be created using the
Visumax femtosecond laser (Carl Zeiss). Excimer laser ab-
lation is then performed using Wavelight Allegretto
WAVE Eye-Q 400 Hz excimer laser (Wavelight GmbH,
Alcon, Fort Worth, TX, USA). After ablation, the flap will
be carefully repositioned, and postoperative medications
are commenced.
Outcomes
We plan to use standard primary and secondary outcomes
measures at 3 months postoperatively, which are reported
in any assessment refractive surgical technique and stand-
ard outcomes in refractive studies. Measurements and out-
comes are based on visual acuity (VA) and refraction that
are performed by trained refractive optometrists and are
repeatedly tested to ensure accuracy and reproducibility.
Our primary outcome measure is refractive predictability,
which is defined as the proportion number of eyes achiev-
ing a postoperative spherical equivalent (SE) within ±0.50
D of the intended target.
Secondary outcome measures include: (1) Efficacy:
defined as the proportion number of eyes achieving a
unaided visual acuity (UAVA) of 20/20 or better postopera-
tively; (2) Safety: defined as the proportion number of eyes
that lost or gained one or more lines of postoperative best-
corrected visual acuity (BCVA) relative to the preoperativeBCVA; (3) Higher-order aberrations (HOAs): measured
using the Bausch and Lomb Technolas Zywave aberrom-
eter with Zywave software version 4.45 (ZYOPTIX Diag-
nostic Workstation, Bausch & Lomb); (4) Contrast
sensitivity: tested using the Vision Contrast Test System
(VCTS) chart (VCTS 6500 contrast sensitivity chart) in six
spatial frequencies.
Sample size
As this is a paired design, non-inferiority trial with a bin-
ary outcome, we calculate the required sample size using
the maximum likelihood method for large sample pro-
posed by Nam (1997) [14]. A review of current literature
reveal that the reported refractive predictabilities in LASIK
and SMILE range from 78.2% to 96.7% [1,14,15] and from
90.0% to 95.6%, [5-8], respectively. The results from our
own audit department estimate our refractive predictabil-
ity at 82% for LASIK (2011, unpublished). We therefore
assumed the refractive predictabilities in LASIK and
SMILE in this study are 82% and 92%, respectively. Thus,
a sample of 67 subjects (134 eyes) will be sufficient to con-
firm non-inferiority with a power of ≥80% and at a 5%
significance level using a 10% non-inferiority margin,
which is the clinically significant difference from our pre-
liminary data. To account for a lost to follow-up rate of
5%, 70 subjects will be recruited.
Randomization and blinding
The random allocation sequence will be generated by a
computer with no blocks or restrictions, and implemen-
ted by concealing the number-coded surgery within
sealed envelopes until just before the procedure. This
randomization process will be performed by a research
assistant masked to the study subjects and participants
will be enrolled by co-investigator surgeons who will
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envelope, that is each subject will receive a different pro-
cedure in each eye at random. In this single-masked trial,
subjects and their caregivers will be masked to the
assigned treatment in each eye. Both procedures will be
performed within the SNEC Refractive Suite, using the
femtosecond laser machine. Clinically, it is impossible to
detect any difference between each procedure postopera-
tively to the untrained eye without the slit-lamp micro-
scope. While the surgeons cannot be masked as they will
be performing the intervention, the outcome assessors
such as nurses, research assistants, and trained optome-
trists will also be masked to the assigned treatment to
improve the objectivity of the research outcomes, as well
as to minimize bias. In the event of adverse events (please
see below), a code-breaking envelope for each subject will
be available.
Data collection
All patients will have data collection forms outlining each
follow-up visit and data to be collected at each visit, which
include visual acuity, refraction results, clinical examin-
ation findings, and the outcome measures as described
above. All data will be securely stored in the SNEC
Refractive Suite and then entered into a password-secure
desktop computer locked within the Singapore Eye
Research Institute, with data back-up into hard drives
done daily. Only the named investigators will have access
to the research data. All data access will be monitored and
controlled by the PI. At the end of the study, the research
data will be entered by the research assistant and stored
for up to 5 years in compliance with any integrity issues
that may arise from any subsequent publications. Follow-
ing that time period the data will be kept under the con-
trol of the PI.
Adverse events
All subjects will be monitored during enrolment into the
study for adverse events. All adverse events or serious ad-
verse event (SAE) will be reported to both the centralized
institution review board and institution heads (Singhealth)
according to the guidelines (http://research.singhealth.
com.sg).
Statistical analyses
Demographic and baseline information will be described,
and eye-specific characteristics will be described for each
treatment. To study the non-inferiority of SMILE to
LASIK, a 90% confidence interval of the difference in
predictability between the two treatments (LASIK minus
SMILE) will be constructed by a method using score
intervals with continuity correction (method #10 in
Newcombe RG, 1998) [15]. If the upper limit of the 90%
confidence interval does not exceed the pre-definednon-inferiority margin of 5%, non-inferiority is con-
firmed. Similarly, for each of the two secondary out-
comes, efficacy, and safety, a 90% confidence interval of
the difference between the two treatments using the
above-mentioned method will be constructed and then
compared with a non-inferiority margin of 5%. Assum-
ing the other secondary outcome, HOA, follows a nor-
mal distribution, a 90% confidence interval of the
difference between the two treatments will be con-
structed through a paired t-test, and then compared with
a non-inferiority margin of 10%. We would not be per-
forming any interim analyses due to the short duration
of follow-up for each outcome measure.
Discussion
In this non-inferiority trial, we aim to demonstrate that
SMILE is just as good as LASIK in terms of refractive
outcome, as we do not expect to see a great improve-
ment to the results from the already established LASIK
procedure. Moreover, this trial may show that SMILE
has additional benefits, such as reduction in higher-
order aberrations that leads to better quality of vision.
On the other hand if we use a superiority trial design
with a small sample size that fails to demonstrate any
difference between LASIK and SMILE, would be incon-
clusive since it does not necessarily prove equivalence.
Thus we use a non-inferiority trial design to compare
our primary and secondary outcomes.
Despite its proven efficacy, LASIK still requires the
use of two laser machines: one for the flap creation and
another for the excimer ablation. This increases the cost
as well as the surgical time for the procedure. SMILE
uses only one laser machine, thus potentially reduces
surgical time and cost. Moreover, SMILE does not
involve any flap creation, which potentially reduces risk
of side effects such as dry eyes. For these reasons,
SMILE is potentially a new, improved form of refractive
surgery, which may supersede LASIK and change clin-
ical practice. There is also potentially a positive impact
on healthcare as surgical time and costs are reduced
with this new, ‘all-in-one’ laser procedure. Moreover, the
needs for enhancements or retreatment are higher in
patients with high myopia, a common condition in
Singapore. SMILE can be used to treat high myopia
without the extra costs involved in visual rehabilitation
following LASIK enhancement.
More importantly, in the longer term we propose that
SMILE may potentially develop into a reversible surgical
procedure. Unlike LASIK which uses an excimer laser to
ablate or destroy corneal tissue, SMILE cuts and
removes a piece of corneal lenticule, which may be
stored and replaced into the cornea at a later time. This
is important as we can potentially reverse the refractive
procedure many years later when the patient’s myopia
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plant the cornea lenticule allows for treatment of corneal
ectasia, reversal or monovision, or even the possibility of
a presbyopic implant. We have done preliminary studies
to demonstrate corneal lenticule viability after ReLEx
[16]; and in an experimental animal study, we demon-
strated proof of principle of a reversible corneal refract-
ive procedure for the first time (unpublished). We were
able to successfully store and re-implant an autologous
stromal lenticule into rabbit eyes with minimal resultant
inflammation and no signs of rejection after 28 days.
This is important as we can potentially reverse the re-
fractive procedure when the patient develops presbyopia.
The ability to re-implant the cornea lenticule allows for
treatment of corneal ectasia, reversal of myopia, monovi-
sion or even the possibility of a presbyopic implant.
In conclusion, this non-inferiority clinical trial that com-
pares SMILE and LASIK will help to determine if this new
refractive procedure, SMILE, has equal or better visual
and refractive outcomes compare to the traditional LASIK
for treatment of myopia. Results of this trial will likely im-
pact clinical practice with potentially further development




LASIK: Laser in-situ keratomileusis; ReLEx: Refractive lenticule extraction;
SMILE: Small incision lenticule extraction.
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